INVO Fertility, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by INVO Fertility, Inc. (Nasdaq: IVF) on June 6, 2025, reporting events occurring on June 2, 2025. The filing details the consummation of a divestiture of the Company's majority holdings in its former wholly-owned subsidiary, NAYA Therapeutics Inc. (NTI).
Key Financial Metrics and Transaction Details
The filing does not provide standard operating metrics such as revenue, profit, or cash flow for the reporting period. Instead, it focuses on the financial structure of the divestiture:
- Divestiture Outcome: The Company divested its majority stake in NTI, retaining only 6,300 shares of NTI Series A Preferred Stock (representing 19.9% of outstanding common stock on an as-if converted basis).
- Redemption Mechanism: The transaction involved the redemption of all outstanding Series C-1 Non-Voting Convertible Preferred Stock at a rate of 113.855837742504 shares of NTI Class A Common Stock per share of C-1 Preferred.
- New Asset: On May 28, 2025, NTI issued a secured convertible promissory note to INVO Fertility in the principal amount of $4,803,175.
- Pro Forma Data: Unaudited pro forma financial statements are included for illustrative purposes as of March 31, 2025, but specific numerical results are not detailed in this text.
Material Changes Versus Prior Period
The primary material change is the shift in ownership structure regarding NAYA Therapeutics Inc. Prior to June 2, 2025, NTI was a wholly-owned subsidiary. Following the redemption of the Series C-1 Preferred stock, INVO Fertility is no longer a holder of NTI common shares and has completed the divestiture of its majority interest. The filing notes a correction to the effective date of the redemption, which was previously reported as May 31, 2025, but officially became effective on June 2, 2025, due to the weekend.
Guidance, Outlook, and Risks
The filing does not contain forward-looking guidance, management commentary on future operations, or specific risk factors beyond the standard disclaimer regarding pro forma information. Management notes that the unaudited pro forma financial information is for illustrative purposes only and is not necessarily indicative of future financial position or operating results following the disposition.
Key Facts for Investor Verification
- Verify the current valuation and terms of the retained 6,300 shares of NTI Series A Preferred Stock.
- Review the specific terms, interest rate, and conversion features of the $4,803,175 secured convertible promissory note issued by NTI.
- Examine the unaudited pro forma financial statements (Exhibit 99.1) to understand the impact of the divestiture on INVO Fertility's balance sheet and operations.
- Confirm the status of the Series C-1 Preferred Stock redemption and ensure no further obligations remain regarding the divested entity.